Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV000660396 | SCV000782476 | uncertain significance | Muscle AMP deaminase deficiency | 2016-08-21 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000660396 | SCV003456955 | uncertain significance | Muscle AMP deaminase deficiency | 2022-06-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 547862). This variant has not been reported in the literature in individuals affected with AMPD1-related conditions. This variant is present in population databases (rs777802711, gnomAD 0.01%). This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 761 of the AMPD1 protein (p.Arg761Cys). |
Revvity Omics, |
RCV000660396 | SCV003826227 | uncertain significance | Muscle AMP deaminase deficiency | 2019-05-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004985060 | SCV005609800 | uncertain significance | Inborn genetic diseases | 2024-06-26 | criteria provided, single submitter | clinical testing | The c.2281C>T (p.R761C) alteration is located in exon 16 (coding exon 16) of the AMPD1 gene. This alteration results from a C to T substitution at nucleotide position 2281, causing the arginine (R) at amino acid position 761 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |